Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged dihydrofuro[3,4-f]quinazoline compounds acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.